The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Reproducibility and replicability of high‐frequency, in‐home digital biomarkers in reducing sample sizes for clinical trials
Open accessAbstract
Introduction: Reproducibility and replicability of results are rarely achieved for digital biomarkers analyses. We reproduced and replicated previously reported sample size estimates based on digital biomarker and neuropsychological test outcomes in a hypothetical 4‐year early‐phase Alzheimer's disease trial. Methods: Original data and newly collected data (using a different motion sensor) came from the Oregon Center for Aging & Technology (ORCATECH). Given trajectories of those with incident mild cognitive impairment and normal cognition would represent trajectories of the control and experimental groups in a hypothetical trial, sample sizes to provide 80% power to detect effect sizes ranging from 20% to 50% were calculated. Results: For the reproducibility, identical P ‐values and slope estimates were found with both digital biomarkers and neuropsychological test measures between the previous and current studies. As for the replicability, a greater correlation was found between original and replicated sample size estimates for digital biomarkers ( r = 0.87, P < .001) than neuropsychological test outcomes ( r = 0.75, P < .001). Discussion: Reproducibility and replicability of digital biomarker analyses are feasible and encouraged to establish the reliability of findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Digital biomarkers used in clinical trials are capable of significantly reducing needed sample sizes.
“digital biomarkers used in clinical trials that are capable of significantly reducing needed sample sizes. 39 , 40”
From Developing digital health technologies for frontotemporal degeneration (2025) · cites this paper as [39]
The Introduction (page unavailable) reports markedly lower projected sample sizes for specific in-home digital biomarkers compared with cognitive tests. The estimates concern hypothetical preclinical Alzheimer’s trials; the paper does not establish that digital biomarkers have reduced sample sizes in clinical trials generally. (LLM, conf=0.84)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Estimating the reproducibility of psychological science
Open Science Collaboration (2015) · Science · doi:10.1126/science.aac4716 · Cited by 8,515
1,500 scientists lift the lid on reproducibility
Baker, M. (2016) · Nature · doi:10.1038/533452a · Cited by 4,209
A Bayesian Perspective on the Reproducibility Project: Psychology
Etz, A., & Vandekerckhove, J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0149794 · Cited by 295 · cited 1×
“13,14 Thus, reproducing and replicating findings from previous studies has become important to increase the rigor of science and reduce study biases with a priori analytical plans.”
BackgroundUse of High-Frequency In-Home Monitoring Data May Reduce Sample Sizes Needed in Clinical Trials
Dodge, H. H., Zhu, J., Mattek, N. C., Austin, D., Kornfeld, J., & Kaye, J. A. (2015) · PLOS ONE · doi:10.1371/journal.pone.0138095 · Cited by 99
Self-citation
Flagged first, then by citations
Research works printed but not linked: 23
- Sabbagh MN, 2020, Alzheimer's Disease Drug Development Pipeline 2020, J Prev Alzheimer's Dis, 7, 66, 10.14283/jpad.2020.12 · DOI
- 10.1111/joim.12191 · DOI · Paper page
- Kaye JA, 2019, Continuously acquired, home‐based digital biomarkers of activity and function are related to Alzheimer's disease neuropathology, J Prev Alzheimer's Dis, 6, S15
- 10.1016/j.gaitpost.2011.09.006 · DOI
- 10.1016/j.dadm.2015.09.006 · DOI
- 10.1080/13854046.2015.1005139 · DOI
- 10.3233/JAD-160079 · DOI
- 10.1016/j.jalz.2013.01.011 · DOI · Paper page
- 10.1212/WNL.0b013e318259e1de · DOI
- National Academies of Sciences Engineering Medicine, 2019, Reproducibility and Replicability in Science
- 10.1016/j.neuroimage.2012.10.086 · DOI
- 10.3791/56942 · DOI
- HayesTL HaglerS AustinD KayeJ PavelM Unobtrusive assessment of walking speed in the home using inexpensive PIR sensors. In:2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.IEEE;2009:7248‐7251. · DOI
- 10.1109/TBME.2009.2036732 · DOI
- Lezak MD, 2004, Neuropsychological Assessment
- 10.2466/pms.1958.8.3.271 · DOI
- Wheeler D, 1981, Wechsler Adult Intelligence Scale‐Revised, Manual
- Wechsler D, 1997, Wechsler Memory Scale (WMS‐III)
- Kaplan E, 1983, The Boston Naming Test
- 10.1001/jamaneurol.2014.803 · DOI · Paper page
- 10.1038/nmeth.3288 · DOI
- 10.1177/0898264309332836 · DOI · Paper page
- 10.1016/j.dadm.2017.02.003 · DOI · Paper page
Cited by
Sorted by citations
Developing digital health technologies for frontotemporal degeneration
Nevler, N., Niehoff, D., Gleixner, A. M., Dodge, S., Vogel, A. P., Hill, D. L., Ducharme, S., Staffaroni, A. M., Yunusova, Y., Au, R., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70082 · Cited by 7
Self-citation
Metadata
- Authors
- Wu, C., Beattie, Z., Mattek, N., Sharma, N., Kaye, J., & Dodge, H. H.
- Affiliations
- Oregon Health & Science University (US)
- Corresponding author
- Wu, Chao‐Yi
- Venue
- Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Publisher
- Wiley
- Published
- 2021-01
- Volume
- 7
- Issue
- 1
- Pages
- e12220-e12220
- ISSN
- 2352-8737 (ISSN-L)
- PMC
- PMC8719347
- OpenAlex
- W4205092819
- Cited by
- 18
- References
- 4
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 1 · 2021: 1
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Center for Advancing Translational Sciences (UL1 TR002369)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Keywords
- digital biomarkers, reproducibility, replicability, sample size determination, clinical trial design, Alzheimer's disease, mild cognitive impairment, neuropsychological assessment, motion sensors, statistical power
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
